Thiamine Therapy for Heart Failure: a Promise or Fiction?

Kattoor, Ajoe John; Goel, Akshay; Mehta, Jawahar L.

doi:10.1007/s10557-018-6808-8

Cited by 13 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is growing evidence that patients with HF have micronutrient deficiencies. Thiamin deficiency has been found to be more prevalent in HF patients than in the general population, with a prevalence reported to vary from 3% to 91% in different studies 192,193 . Supplementation has been argued as a possible treatment strategy.…”

Section: Non‐cardiac Specificmentioning

confidence: 99%

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)

Meijers

Bayés‐Genís

Mebazaa

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

New biomarkers are being evaluated for their ability to advance the management of patients with heart failure. Despite a large pool of interesting candidate biomarkers, besides natriuretic peptides virtually none have succeeded in being applied into the clinical setting. In this review, we examine the most promising emerging candidates for clinical assessment and management of patients with heart failure. We discuss high-sensitivity cardiac troponins (Tn), procalcitonin, novel kidney markers, soluble suppression of tumorigenicity 2 (sST2), galectin-3, growth differentiation factor-15 (GDF-15), cluster of differentiation 146 (CD146), neprilysin, adrenomedullin (ADM), and also discuss proteomics and genetic-based risk scores. We focused on guidance and assistance with daily clinical care decision-making. For each biomarker, analytical considerations are discussed, as well as performance regarding diagnosis and prognosis. Furthermore, we discuss potential implementation in clinical algorithms and in ongoing clinical trials.

show abstract

Section: Non‐cardiac Specificmentioning

confidence: 99%

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)

Meijers

Bayés‐Genís

Mebazaa

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…Both of these two reactions are indispensable steps for aerobic metabolism and ATP production. As a cofactor of TKT enzyme, TPP is important for the pentose phosphate pathway, maintaining cell redox through higher formation of reduced nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione (GSH; Zastre et al, 2013 ; Manzetti et al, 2014 ; Kattoor et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

“…However, some substances can affect thiamine level through its absorption, metabolism, or its activation. Decreased thiamine intake and poor absorption may occur during cardiac cachexia and splanchnic congestion ( Kattoor et al, 2018 ). Considering that thiamine loss is associated with urinary clearance, diuretics are identified as drugs causing thiamine deficiency, especially in patients with cardiovascular diseases ( Zenuk et al, 2003 ).…”

Section: Introductionmentioning

confidence: 99%

Protective Role of Vitamin B1 in Doxorubicin-Induced Cardiotoxicity in Rats: Focus on Hemodynamic, Redox, and Apoptotic Markers in Heart

et al. 2021

View full text Add to dashboard Cite

Up until now, the specific mechanisms involved in doxorubicin (DOX)-induced cardiotoxicity have not been fully elucidated. Since thiamine deficiency is associated with myocardial dysfunction and it may lead to cardiomyopathy, we aimed to investigate whether thiamine (Vitamin B1) treatment provides cardioprotection and modulates DOX mediated subchronic cardiotoxicity as well as to determine possible mechanisms of its effects. The study involved 48 Wistar albino rats divided into four groups: healthy non-treated rats and healthy rats treated with thiamine and DOX rats without treatment and DOX rats treated with thiamine. DOX was applied as a single i.p.injection (15mg/kg), while thiamine treatment lasted 7days (25mg/kg/dayi.p.). Before and after the treatment hemodynamic changes were monitored in vivo by echocardiography. When the protocol was completed, animals were sacrificed and rat hearts were isolated in order to evaluate parameters of cardiac oxidative stress [superoxide anion radical-O2−, hydrogen peroxide-H2O2, nitric oxide-NO−, index of lipid peroxidation-thiobarbituric acid (TBA) reactive substances (TBARS), superoxide dismutase – SOD, catalase (CAT), and reduced glutathione-GSH] and apoptosis (Bax, Bcl-2, caspases). DOX treatment significantly reduced the ejection fraction, while thiamine treatment led to its minor increase in the DOX-treated group. In that sense, heart oxidative stress markers were significantly increased in DOX-treated rats, while therapeutic dose of thiamine decreased the levels of free radicals. Our study demonstrated the promising ameliorative effects of thiamine against DOX-induced cardiotoxicity through modulation of oxidative stress, suppression of apoptosis, and possibility to improve myocardial performance and morphometric structure of rats` hearts.

show abstract

“…Thiamine deficiency in HF has been regularly reported [ 14 , 151 , 152 ] and could reach about 90% of hospitalized HF patients receiving furosemide [ 153 , 154 ], a loop diuretic which is thought to participate in this deficiency [ 155 , 156 ], although this hypothesis has not been systematically confirmed in trials [ 151 ]. It is difficult to accurately assess the rate of thiamine deficiency in HF as the available data comes from studies with very specific designs, including different HF populations (age range, medications, underlying nutrition status…).…”

Section: B Vitamins In Heart Failurementioning

confidence: 99%

Metabolic Therapy of Heart Failure: Is There a Future for B Vitamins?

Piquereau

Boitard

Ventura‐Clapier

et al. 2021

IJMS

View full text Add to dashboard Cite

Heart failure (HF) is a plague of the aging population in industrialized countries that continues to cause many deaths despite intensive research into more effective treatments. Although the therapeutic arsenal to face heart failure has been expanding, the relatively short life expectancy of HF patients is pushing towards novel therapeutic strategies. Heart failure is associated with drastic metabolic disorders, including severe myocardial mitochondrial dysfunction and systemic nutrient deprivation secondary to severe cardiac dysfunction. To date, no effective therapy has been developed to restore the cardiac energy metabolism of the failing myocardium, mainly due to the metabolic complexity and intertwining of the involved processes. Recent years have witnessed a growing scientific interest in natural molecules that play a pivotal role in energy metabolism with promising therapeutic effects against heart failure. Among these molecules, B vitamins are a class of water soluble vitamins that are directly involved in energy metabolism and are of particular interest since they are intimately linked to energy metabolism and HF patients are often B vitamin deficient. This review aims at assessing the value of B vitamin supplementation in the treatment of heart failure.

show abstract

Thiamine Therapy for Heart Failure: a Promise or Fiction?

Cited by 13 publications

References 20 publications

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)

Protective Role of Vitamin B1 in Doxorubicin-Induced Cardiotoxicity in Rats: Focus on Hemodynamic, Redox, and Apoptotic Markers in Heart

Metabolic Therapy of Heart Failure: Is There a Future for B Vitamins?

Contact Info

Product

Resources

About